Peer AI raises $12.1M to speed up drug approvals with agentic AI
Peer AI, a San Francisco-based startup specializing in AI-powered regulatory workflows for life sciences, has secured $12.1 million in funding to accelerate drug approval processes. The round was led by Flare Capital Partners and SignalFire, with participation from Greycroft, Atria, Alumni Ventures, Gaingels, and Mana Ventures.
For eeNews Europe readers, this development highlights how domain-specific AI and human-in-the-loop systems are reshaping data-intensive processes in healthcare — a space with growing crossover into intelligent automation, life sciences tech, and digital infrastructure.
AI-driven workflow targets drug development bottlenecks
Regulatory documentation remains one of the biggest obstacles in drug development, requiring over 200,000 pages of documentation across 1,500 unique documents per drug. According to Peer AI, nearly one-third of FDA submissions have quality issues, leading to rejections and delays averaging over a year.
Peer AI’s agentic AI platform deploys specialized, domain-specific AI agents that work alongside human experts through an intuitive interface. This “human-in-the-loop” design allows medical writers to verify and edit content at key control points — ensuring accuracy and compliance while dramatically speeding up workflow.
Customers, including top 20 pharmaceutical firms and emerging biotechs, have reported 55–94% faster document drafting times, significant cost reductions, and higher document consistency. For example, medical writing teams cut clinical study report (CSR) drafting time from 40 to 17 days and reduced protocol turnaround from up to eight weeks to just one week.
“Our vision is to create an intelligent regulatory workflow that connects documentation, data, and decision-making to speed drug approvals,” said Anita Modi, CEO and co-founder of Peer AI. “Documentation drives every step of the drug development process. We’re putting agentic AI in the hands of expert medical writers to create documents faster, improve quality, and, ultimately, accelerate treatments to patients.”
Building the regulatory backbone for life sciences
Peer AI’s approach integrates AI agents designed for specific tasks such as data extraction, authoring, formatting, and final validation. A peer-led deployment model ensures smooth onboarding and training by experienced medical writers.
The company’s investors see the potential for agentic AI to redefine how regulatory documents are produced across the industry. “We see enormous opportunity in GenAI-based tools to unlock value in drug discovery and clinical development processes,” said Ian Chiang, partner at Flare Capital Partners. “Peer AI’s distinctive approach and specialized agentic AI platform are shaped by in-house medical writer expertise.”
Sooah Cho, partner at SignalFire, added, “They’re establishing the foundational regulatory backbone for life sciences to transform a historically fragmented, manual process with a unified agentic platform and intuitive user experience that brings experts in the loop at the right times.”
With the regulatory documentation market estimated at $15 billion, Peer AI plans to use the new funding to expand product development and commercial operations. The company’s rapid adoption — with daily use tripling in 2025 and total platform activity growing sixfold — points to strong validation in a market eager for efficiency and compliance.
Peer AI’s agentic platform is available now, with the team showcasing solutions at upcoming industry events including RAPS Convergence, AMWA Medical Writing & Communications Conference, and the CNS Summit later this year.
If you enjoyed this article, you will like the following ones: don't miss them by subscribing to :
